Clinical trial
A Single-arm, Prospective, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
NCT04556071 is registered in ClinicalTrials.gov with Xiaoxiang Chen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Prospective, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
- Lead sponsor
- Xiaoxiang Chen
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- November 6, 2020
- Completion date
- October 1, 2022
- Enrollment
- 32 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adnexal diseases, angiogenesis, antineoplastic agents, bevacizumab, brca1 mutation, brca2 mutation, carcinoma, carcinoma, ovarian epithelial, endocrine gland neoplasms, endocrine system diseases, enzyme inhibitors, fallopian tube neoplasms, genital diseases, female, genital neoplasms, female, gonadal disorders, homologous recombination deficiency, molecular mechanisms of pharmacological action, neoplasms, neoplasms by histologic type, neoplasms by site, neoplasms, glandular and epithelial, ovarian diseases, ovarian neoplasms, urogenital neoplasms